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Elevated glucose acts directly on
osteocytes to increase sclerostin
expression in diabetes
Donna M. Pacicca 1,2*, Tammy Brown1, Dara Watkins1, Karen Kover1, Yun Yan1,
Matthew Prideaux3 & Lynda Bonewald3
Bone quality in diabetic patients is compromised, leading to weaker bones and increased fracture
risk. However, the mechanism by which this occurs in diabetic bone remains to be fully elucidated.
We hypothesized that elevated glucose and glucose variation would affect the function of osteocytes,
essential regulators of bone homeostasis and quality. To first test this hypothesis, we used the IDG-SW3
osteocyte-like cell line to examine the effects of glucose levels on osteocyte function and viability in
vitro. We confirmed our in vitro findings using the in vivo streptozotocin-induced (STZ) diabetic rat
model and ex-vivo cultured osteocytes from these rats. IDG-SW3 cells cultured under high glucose
conditions displayed significantly increased Sost mRNA(100-fold) and sclerostin protein, a negative
regulator of bone formation(5000-fold), compared to cells in control media. mRNA expression of
osteoblast markers such as Osx, Ocn and Col1a1 was unaffected by glucose. Factors associated with
osteoclast activation were affected by glucose, with Rankl being upregulated by low glucose. Opg was
also transiently upregulated by high glucose in mature IDG-SW3 cells. Induction of diabetes in SpragueDawley rats via a single dose of STZ (70 mg/kg) resulted in elevated maximum glucose and increased
variability compared to control animals (670/796 vs. 102/142 mg/dL). This was accompanied by
increased Sost/sclerostin expression in the osteocytes of these animals. These results show that glucose
levels directly regulate osteocyte function through sclerostin expression and suggest a potential
mechanism for the negative impact of diabetes on bone quality.
Diabetes mellitus is a disease with an increasing impact worldwide. Currently, an estimated 422 million people
have diabetes1, and it has moved up to be the 6th leading cause of death worldwide2. Fluctuations in blood glucose
have a detrimental effect on heart, kidney, retinal and vascular tissues, and can lead to myocardial and cerebral
infarction, kidney failure, blindness, neuropathy and infections that can result in amputation3. In addition, diabetic patients are known to have an increased risk for fracture that appears to be independent of bone mineral
density. While type 1 diabetes patients generally have modest reductions in BMD, their relative risk for hip fracture is significantly higher than predicted4. In the type 2 patients, who generally have normal to elevated BMD,
the relative risk for hip fractures is 1.7, also higher than expected or predicted4. While the fall risk for diabetic
patients is also increased, this alone does not account for the increased fracture risk observed in these patients5.
Maintaining bone quality and integrity requires the coordinated actions of osteoblasts, which synthesize new
bone matrix and osteoclasts, which resorb old or damaged bone. Osteocytes, cells which reside within the mineralized bone matrix, are responsible for regulating the activities of osteoblasts and osteoclasts in response to
mechanical and biochemical signals6,7. Osteocytes have been shown to induce bone resorption via their production of the osteoclast-activating factor Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL)8,9 and
to inhibit bone formation by secreting sclerostin10–12, which is encoded by the Sost gene and is an important
negative feedback regulator of the Wnt pathway13,14. Interestingly, serum sclerostin has been shown to be elevated
in both type 1 and type 2 diabetes patients15,16. As sclerostin is primarily produced by osteocytes, this suggests
that changes in glucose concentration may have a profound effect on the cells most responsible for maintaining
bone health. More specifically, increased glucose variability as demonstrated by significant elevation and depression of blood glucose level well above and below the normal 80–140 mg/dL range may lead to adverse effects on
osteocytes.
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Figure 1. Elevated glucose levels do not affect cell number or activity of IDG-SW3 cells but regulate the
expression of glucose transporter enzymes. (A) No change in approximate cell number was observed when
culturing IDG-SW3 cells under high glucose conditions (as measured by total DNA content), but cell number
was significantly decreased under low conditions by day 35 (p = 0.022). (B) No change in glucose utilization is
observed when normalized to cell number. (C) Lactate production is not affected by glucose levels in IDG-SW3.
Lactate dehydrogenase activity in cell lysate (D) or culture media (E) is unaffected by glucose. The transporter
enzymes Glut1 (F) and Glut3 (G) are upregulated by low glucose and downregulated by high glucose culture
conditions (Glut 1 CtLow 22–27, CtHigh 25–27 vs. CtNormal 22–27; Glut 3 CtLow 26–28, CtHigh 26–30 vs. CtNormal
26–28, p < 0.009, n = 3). Graphs show individual data points, mean and SEM for fold change in gene expression
compared to control. 10 mM Glucose = normal levels, 2.5 mM Glucose = Low Glucose, 25 mM Glucose = High
Glucose, 15 mM Mannitol/10 mM Glucose = Control for Osmolarity.

To investigate the role of glucose variability on osteocytes, we first used the IDG-SW3 cell line to examine the
effects of varying glucose concentration on osteocytes in vitro. This cell line has been shown to differentiate from
an osteoblast to an osteocyte-like phenotype during culture and, when fully differentiated, to recapitulate the
phenotype of mature osteocytes in vivo17. In addition, we obtained serum and cortical bone specimens from normal and diabetic rats and isolated a purified primary osteocyte population to evaluate glucose effects on primary
osteocyte function. We have used these in vivo and in vitro models to determine the effects of high glucose levels
on osteocyte function and viability, which may have important implications for bone quality and susceptibility
to fracture.

Methods

In vitro studies.

IDG-SW3 cell line culture. The IDG-SW3 cell line was cultured as previously described17.
Briefly, IDG-SW3 cells were expanded in permissive conditions (33 °C in alpha-MEM with 10% FBS, 100 U/
ml penicillin, 50 µg/ml streptomycin, and 50 U/ml IFN-γ (Thermo Fisher Scientific)) on rat tail type I collagen-coated 150 cm2 culture dishes (Corning Inc.), then plated at 8 × 104 cells/cm2 in osteogenic conditions (37 °C
in DMEM (Mediatech Inc.) with 50 µg/ml ascorbic acid and 4 mM β-glycerophosphate (Sigma-Aldrich Corp., St.
Louis, MO) under three different glucose concentrations: Low (2.5 mM equivalent to 45 mg/dl), Normal control
(10 mM equivalent to 180 mg/dl), High (25 mM equivalent to 450 mg/dl); Mannitol control (glucose 10 mM with
mannitol 15 mM (Sigma-Aldrich Corp., St. Louis, MO)) was used as a control for high osmolarity. Media was
changed daily for 35 days. Cells were harvested at 3, 7, 14, 21, 28 and 35 days. There were three biological replicates for each of the conditions.
Measurement of metabolic activity in vitro. Media glucose concentrations in the IDG-SW3 cell cultures were
obtained via glucometer (OneTouch Ultra 2, Lifescan, Milpitas, CA) from all wells at baseline (1 day pre-harvest)
and at each harvest. These measurements were then used to calculate the amount of glucose utilized. Note that the
lower limit of glucose measurement by glucometer is 20 mg/dL, with overall SEM of ±20% per manufacturer. As
such, three measurements were obtained for each sample and averaged. We validated glucometer measurements
of media with glucose at several different concentrations prior to initiation of experiments.
As previous studies have shown that bone primarily uses glycolysis for energy generation18, L-lactate assay
(Eton Bioscience, San Diego, CA) was also performed on SW3 media per manufacturer’s instructions. Briefly, 50
µL L-lactate assay solution was added to a 96-well plate containing 50 µL standards and samples in duplicate, and
incubated at 37°C for 30 minutes. The reaction was stopped with the addition of 0.5 M acetic acid and absorbance
measured at 450 nm. The standards were used to interpolate lactate concentration.
We used LDH levels in cell lysate to estimate viability, with LDH activity in culture media to estimate cell
death. LDH assay (Lactate dehydrogenase assay, Tox-7 kit, Sigma-Aldrich, St. Louis, MO) was performed on SW3
cell lysate as well as culture media per manufacturer’s instructions. Briefly, cells were lysed after a 50 µL sample
of media was aliquoted. The lysed cells were centrifuged at 250 g for 4 minutes and the supernatant aliquoted.
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Figure 2. Sclerostin is upregulated by elevated glucose in IDG-SW3 cells. (A) Ocn mRNA shows a transient
significant upregulation in response to low glucose (CtLow 24–27, CtHigh 26–28 vs. CtNormal 26–28). (B) Sost
mRNA is strongly upregulated in response to high glucose in mature IDG-SW3 cells (CtHigh 23–30 vs. CtNormal
25–33, p < 0.0001, n = 3), as is (C) sclerostin protein (p < 0.0001, n = 3).

Samples were then placed into a 96-well plate with 100 µL of the assay mixture, covered and incubated at room
temperature for 30 minutes. 1 N HCl was used to terminate the reaction. Absorbance of samples was read at 490
and 690 nm (Epoch BioTek plate reader, Winooski, VT).
Determination of relative cell number through DNA quantitation. IDG-SW3 cell cultures were normalized to
approximate cell number using total DNA measurements, as mineralization did not allow for direct counting of
differentiated cells. IDG-SW3 cells were grown for three days, then the cells were trypsinized, counted and placed
into Trizol. Total DNA was isolated using the manufacturer’s protocol. Optical density was measured using a
NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE) to calculate concentration of DNA. This was related
back to the counted cell number to determine the approximate DNA concentration per cell (9.2105E-4 pg/cell).
Assessment of matrix mineralization. IDG-SW3 cells were fixed with 10% formalin (Sigma-Aldrich, St. Louis,
MO) for 5 minutes, washed with PBS, stained with 2% alizarin red S for 5 minutes, and repeatedly washed in PBS
until no stain was present in solution. Plates were photographed, and then the dye was leached from the cultures
using 500 µL 10% cetylpyridinium chloride solution at 37 °C for 30 minutes. Absorbance was measured at 570 nm.
Assessment of gene expression by real-time PCR. TRIzol reagent was used to isolate RNA: the digested bone chips
were first placed in 1 ml TRIzol then pulverized in liquid nitrogen; the primary bone cell and IDG-SW3 cultures
were scraped into 1 ml TRIzol. Total RNA was extracted using chloroform (Sigma) and purified using isopropanol (Sigma) according to the manufacturer’s instructions. RNA was washed in 70% ethanol and resuspended
in RNase-free water. DNA contaminants were removed by digestion with DNase I (DNA-free DNA Removal
Kit, Applied Biosystems, Carlsbad, CA) for 30 minutes at 37 °C. 2–4 µg of RNA were reverse transcribed to cDNA
using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA) according to
the manufacturer’s instructions. Real-time PCR was performed on a Step One Plus cycler using 25 ng of template
cDNA with 2x Taqman Gene Expression Master Mix and Taqman gene arrays for Sost, Actb, Ocn, Opg, Rankl,
E11, Dmp1, Glut1, Glut2, Glut3 and Glut4 (all from Applied Biosystems, Carlsbad, CA).
Gene expression was normalized to the housekeeping gene Actb and relative quantification was calculated
with the 2−ΔΔCT method19 using the normal glucose as control for low glucose, with the mannitol plus glucose as
control for high glucose. Normal glucose vs. mannitol was also examined to evaluate for any effect of osmolarity.
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Figure 3. Effects of varying glucose concentration on matrix mineralization and expression of bone regulatory
genes. (A) Matrix mineralization by IDG-SW3 cells is unaffected by glucose concentration. (B) Osx and
(C) Col1a1 mRNA expression is not regulated by high glucose. (D) Kera mRNA, a marker of osteoblast
differentiation, is upregulated under high glucose culture conditions.

In vivo studies. N.B.: the tissues and data collected for this study were taken from animals already approved
for experiments in the laboratories of Drs. Kover and Yan, therefore maximizing tissue usage and reducing animal
wastage. The University of Missouri at Kansas City (UMKC) animal facility is operated as a specific pathogen-free,
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC)-approved facility and animal care and husbandry meet the requirements in the Guide for the Care and use of Laboratory Animals (8th
edition), National Research Council. All animal experiments were approved by the UMKC Institutional Animal
Care and Use Committee (IACUC) in accordance with relevant federal regulations and guidelines (protocols
1229, 1603).
Induction of diabetes in vivo. In Drs. Kover and Yan’s laboratory, chemical diabetes was induced in randomly
allocated 8 week old healthy male Sprague-Dawley rats (Harlan Sprague Dawley Inc, Indianapolis, IN) via a single dose of intraperitoneal streptozotocin (70 mg/kg, Sigma-Aldrich Corp., St. Louis, MO) versus normal saline
for controls. Induction of diabetes was confirmed by 48 hours in all diabetic animals via tailstick glucose measurement. A subcutaneous osmotic insulin pump (DURECT Corporation, Cupertino, CA) was inserted into the
diabetic rats at day 8 providing insulin-aspart (Novolog ) 1U/kg/day (Novo Nordisk, Plainsboro, NJ) which was
used to maintain a controlled level of hyperglycemia (per lab protocol). Animals were housed individually with
free access to food and water. Water intake and weight were monitored. Tailstick blood glucose measurements
were obtained daily in diabetic and selected control animals. In addition, selected rats from both groups had continuous glucose monitoring (q 5 minute) via a subcutaneous sensor (Medtronic, Northridge, CA) for three days.
Rats were sacrificed at 8 weeks post injection. No adverse events were noted.

®

Isolation of primary rat osteocytes. Long bones (femur, tibia or humerus) were harvested from rats and soft
tissue was mechanically removed from the surface of the bone. A bone cutter was used to split the bone in half
and remove the marrow, rinsing in sterile Dulbecco’s phosphate buffered saline (PBS, Mediatech, Inc. Manassas,
VA) simultaneously. Once the soft tissue and marrow were removed, the bones were minced into 1–2 mm chips,
washed in PBS and placed into α-minimum essential medium (α-MEM, Mediatech, Inc. Manassas, VA) with 1%
penicillin/streptomycin (P/S, 10,000 U/mL, 15140122, Invitrogen, Carlsbad, CA). The chips were put through
six cycles of alternating 1 mg/mL collagenase digests (Sigma-Aldrich Corp., St. Louis, MO) and 14 mM ethylene
diaminetetraacetic acid (EDTA, Sigma-Aldrich Corp., St. Louis, MO) with 1% bovine serum albumin (BSA,
Sigma-Aldrich Corp, St. Louis, MO) in an incubator set at 37 °C for 20 minutes to remove tissue and mineral.
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Figure 4. Analysis of glucose levels and serum sclerostin in diabetic animals. Blood glucose levels from tailstick
(A) and 72-hour continuous subcutaneous monitoring (B) demonstrating significant elevation in blood glucose
mean, maximum and range. (p < 0.0001, n = 11 diabetic, 5 control). (C) Serum ELISA results from normal vs.
diabetic (p = 0.006, n = 8 diabetic, 7 control).
After each cycle, the chips were centrifuged at 400 g for 5 minutes with PBS. Following the 6 cycles, the bone chips
were used for culture or downstream RNA analysis.
Primary osteocyte-enriched culture. An osteocyte-enriched population of cells was isolated from the long bones
of the 16 week old rats as described previously. Cells were obtained from the supernatants of digests 5 and 6,
centrifuged at 400 g for 5 minutes and re-suspended in 3 mL of culture media (α-MEM supplemented with 1%
P/S, 5% fetal bovine serum (FBS, Hyclone Laboratories, Logan, UT), 5% calf serum (CS, Hyclone Laboratories,
Logan, UT)). These cells, with a portion of the bone chips from each animal, were then cultured for 72 hours in
6-well collagen-coated plates (Collagen I, rat tail, Fisher Scientific, Hampton, NH) in a total of 1.5 mL of culture media. After 72 hours, 1 mL of culture media was added to each well. At day 5 of culture, the media was
replaced with 2 mL fresh culture media containing either 25 mM glucose or 5.5 mM glucose with 19.5 mM mannitol (Sigma-Aldrich Corp., St. Louis, MO). At day 7, media, cells and chips were harvested. Cells and chips were
placed in 1 mL of Tri-Reagent (Molecular Research Center, Inc. Cincinnati, OH), flash frozen in liquid nitrogen,
and stored at −80 °C to be used for RNA isolation. Conditioned media was flash frozen in liquid nitrogen, and
stored at −80 °C to be used for assays. There were three biological replicates for each of the conditions.
Measurement of sclerostin protein ex vivo and in vitro. Sclerostin ELISA assay (R&D Systems, Minneapolis,
MN) was performed on SW3 media harvested at days 21, 28 and 35 of culture, rat serum and rat primary bone
cell media per manufacturer’s instructions. Briefly, 50 µL diluent solution was added to a conjugated 96-well
plate containing 50 µL standards and samples in duplicate, and incubated at 37 °C for 3 hours. 100 µL of Mouse
SOST conjugate was added per well and incubated at 37 °C for 1 hour. 100 µL of substrate solution was added per
well and incubated in the dark at 37 °C for 30 minutes. The reaction was stopped with the addition of 100 µL of
stop solution and absorbance measured at 450 nm, with readings at 540 nm obtained for wavelength correction.
Standards were used to interpolate sclerostin concentration.
Immunohistochemistry. Digested bone chips (from random segments of bone) were fixed in 10% formalin for
24 hours and then decalcified for two weeks in 14% Ethylenediaminetetraacetic acid (EDTA, Sigma). The bone
chips were processed through graded ethanol and xylene, paraffin-embedded and 6 µm sections were cut onto
Superfrost Plus slides (Thermo Fisher Scientific). Sections were dewaxed in Clear-rite (Thermo Fisher Scientific,
Kalamazoo, MI) and rehydrated prior to immunostaining. Sections were then incubated 1 hour at room temperature in blocking solution (0.2% gelatin (Knox, Winona, ON Canada); 0.5% nonfat dry milk (Wal-Mart,
Bentonville, AR), 0.02% Tween-20 (Sigma), 1% serum of secondary antibody), followed by goat anti-sclerostin
antibody (1:250, R&D Systems Inc., Minneapolis, MN) (1:500) overnight at 4 °C. Rabbit anti-goat antibody
(1:200, Vector ABC kit, Vector, Burlingame, CA) was then incubated per kit instructions for 1 hour at room temperature for secondary antibody and avidin-biotin complex reaction, followed by DAB exposure for 1.5 minutes.
Slides were counterstained with methyl green, rinsed and cover-slipped and imaged at 100x magnification. Cell
counting was performed as an average of 6 images under 40x magnification, with percent positive cells expressed
as number of positively stained cells over the total number of methyl green stained cells times 100. At least two
slides were used for each specimen.
Fluorescent Immunohistochemistry. Whole bones (tibia) from control and diabetic rats were fixed in 10% formalin for 24 hours, then decalcified for 2–3 weeks in 14% EDTA. Bone sections were prepared as described
above. These were dewaxed and rehydrated prior to immunostaining. Sections were then incubated in blocking
solution, followed by goat anti-sclerostin antibody (1:250, R&D Systems Inc., Minneapolis, MN) overnight at
4 °C. Cy3-donkey anti-goat antibody (Jackson ImmunoResearch, Burlingame, CA) was then added after rinsing
slides and incubated for 1 hour at room temperature. Slides were incubated with DAPI (Sigma) for 30 minutes at
room temperature, rinsed and cover-slipped and imaged with a laser confocal microscope (Carl Zeiss Microscopy
GmbH, Munich, Germany). Cell counting was performed as an average of 9 images of diaphyseal bone obtained
from standardized regions (proximal, middle and distal regions from each cortex) under 25x oil magnification in
blinded fashion. Percent positive cells were expressed as number of positively stained cells over the total number
of DAPI-positive cells times 100. A minimum of two sections per bone were used for each specimen.
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Figure 5. Sost expression is increased in diabetic bone. (A) Sost expression is increased almost 4-fold in
diabetic bone (Ctdiabetes 30 vs. Ctcontrol 32) but (B) Ocn mRNA expression is unaffected. (p = 0.012, n = 8 diabetic,
8 control). (C) Sost expression correlated with glucose expression (p = 0.06, n = 8 diabetic, 6 control). Primary
osteocyte culture from control and diabetic animals showed maintenance of Sost mRNA (D) and sclerostin
protein expression (E) at significantly high levels independent of media glucose concentration (p < 0.0001 for
both (D) and (E), n = 2 for each group, 3 replicates per treatment).

Statistical analysis. Statistical analysis was performed using Prism 6 software (GraphPad, San Diego, CA).
Linear and non-linear curve regressions were used for assay interpolation, using R squared value greater than
0.99 for goodness of fit. One- and two-way ANOVA with Tukey post hoc test were used to determine significant
differences compared to controls, with p < 0.05 being considered significant. Data shown are mean ± SEM.

Results

Cell culture.

High glucose does not affect osteocyte viability in vitro. To interrogate the role of glucose in
regulating osteocyte function and sclerostin in vitro, we first utilized the osteocyte-like cell line IDG-SW3. Longterm culture of IDG-SW3 cells under high glucose conditions did not affect the cell number; culturing the cells
under low glucose conditions did significantly reduce the cell number after day 28 (Fig. 1A).
The data were then normalized to the estimated cell number (obtained indirectly via total DNA) to account for
differences in cell density when cultured under different glucose levels. No differences in glucose utilization under
the different culture conditions were observed when normalized to cell number (Fig. 1B). Similarly, no differences
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Figure 6. Sclerostin protein expression is elevated in bone chips from diabetic animals. Immunohistochemical
staining for sclerostin in bone chips from cortical bone show increased sclerostin expression in diabetic bone
(B) compared to control bone. (A) Non-immune control is shown in. (C) Sclerostin positive osteocytes are
indicated by black arrows. (D) The percentage of sclerostin positive osteocytes is significantly increased in the
diabetic bone pieces (p = 0.021, n = 5 per group).

were observed in production of the glucose metabolite, lactate, by the IDG-SW3 cells under high or low glucose
culture conditions (Fig. 1C).
Lactate dehydrogenase (LDH) assays were performed on both cell lysate and media, with lysate measurement
reflecting live cell activity and media LDH proportional to numbers of dead cells. There were no significant differences observed in LDH levels in the cell lysate when corrected for cell number, indicating no differences in cell
viability between glucose conditions (Fig. 1D). No decrease in LDH in conditioned media was noted with either
high or low glucose (Fig. 1E). This suggests that high or low glucose culture conditions do not induce cell death in
the IDG-SW3 cells. The differences between the earlier and later time points likely reflect decreased cytoplasmic
volume of the more mature osteocytic cells.
Local glucose concentrations regulate glucose transporter enzyme expression in osteocytes. The glucose transporter
enzymes play essential roles in the transportation of glucose across the plasma membrane. The expression of the
glucose transporters Glut1-Glut4 was assessed in IDG-SW3 cells by real-time PCR. Glut1 mRNA expression was
higher than Glut3, whereas Glut2 and Glut4 were not detectable (data not shown) in the IDG-SW3 cells. The
expression of both Glut1 and Glut3 mRNA was significantly upregulated in culture under low glucose conditions
and inhibited by high glucose (Fig. 1F,G). Insulin receptor expression was not affected by glucose concentration
(Supplemental Fig. 1).
High glucose culture conditions promote sclerostin expression in osteocytes in vitro. IDG-SW3 cells were cultured
under low and high glucose conditions to evaluate the effects on bone-specific genes. Ocn expression was temporally upregulated in the mature IDG-SW3 cells under low glucose conditions (Fig. 2A). Most notably, high glucose significantly and robustly increased Sost mRNA expression in the mature, osteocyte-like IDG-SW3 cultures
compared to mannitol control 50–150 fold (Fig. 2B). The increase in Sost mRNA was accompanied by an increase
in sclerostin production by the cells cultured under high glucose 6000 fold (Fig. 2C).
Glucose levels do not affect mineralization in vitro but regulate markers associated with bone formation and resorption.
As sclerostin is known to regulate bone formation and mineralization10,20, we examined the mineral deposition and osteoblast marker expression of IDG-SW3 cells cultured under high and low glucose. Maximal
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Figure 7. Sclerostin protein expression is increased in the tibiae of diabetic rats. Immunofluorescence staining
for sclerostin in cortical bone shows increased sclerostin positive osteocytes (red staining, white arrows) in the
tibiae from diabetic animals (B) compared to control. (A) Non-immune control is shown in. (C) The percentage
of sclerostin positive osteocytes is significantly increased in the diabetic bone (p = 0.027, n = 4 diabetic, 6
control).
mineralization of the cells was reached at day 21 and was unaffected by either high or low glucose (Fig. 3A). The
expression of the osteoblast marker genes osterix (Osx) and Col1a1, was unaffected by glucose (Fig. 3B,C), as were
the osteocyte marker genes Dmp1 and E11 (Supplemental Data).

Animal studies. Streptozoticin injection induces high glucose levels in vivo. Tail stick and continuous glucose monitoring (CGMS) glucose measurements were taken from 5 control and 11 diabetic rats to determine
the glucose levels resulting from inducing diabetes in these animals. There were significant differences in mean
and maximum glucose as well as glucose range, which is a marker of variability (Fig. 4A). Glucose variability and
maximum glucose were significantly increased in the diabetic vs. control animals (670/796 vs. 102/142 mg/dL)
with CGM (Fig. 4B). No adverse events were noted. Unexpectedly, serum sclerostin levels were significantly lower
in the diabetic animals compared with control rats (Fig. 4C).
Diabetes upregulates sclerostin expression in osteocytes in vivo. To determine the effects of glucose on Sost expression in osteocytes in vivo, we analyzed RNA from cortical bone from control and diabetic rats, which had been
sequentially digested to remove cells from the bone surface. To confirm that the digested bone contained primarily osteocytes, real-time PCR demonstrated undetectable expression of the gene Kera, coding for the osteoblast marker keratocan21 (data not shown). Increased expression of Sost was observed in the digested bone from
diabetic rats compared to controls (Fig. 5A), in contrast with the decreased levels of sclerostin in the serum. No
difference was observed Ocn mRNA expression (Fig. 5B).
To examine the response of osteocyte populations from diabetic and control rats to high glucose, primary
osteocyte-enriched cells and bone chips were isolated from rat cortical bone and cultured under normal and
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Figure 8. Sost mRNA (A) and sclerostin protein (B) are similarly regulated by chronic high glucose in both
primary osteocytes and IDG-SW3 cells (n = 3, p < 0.0001). However, the primary osteocytes from animals
exposed to high glucose are not further affected by high glucose culture.

high glucose conditions. Osteocytes from the diabetic rats expressed high levels of Sost mRNA and sclerostin
compared to those from the control rats (Fig. 5D,E). This was consistent across animals. This was observed despite
culturing cells in normal media. Culturing the diabetic osteocytes in high glucose for 7 days did not significantly
change expression. There was a trend towards a significant correlation between Sost mRNA and glucose taken
from the animals (p = 0.06) (Fig. 5C).
To evaluate whether the increased Sost mRNA expression in the cortical bone from the diabetic rats corresponds to increased sclerostin production, bone from the rats were assessed for sclerostin protein by immunohistochemistry (for the digested bone chips) as well as by confocal using immunofluorescence (for whole bone
sections). Increased intensity of sclerostin staining was observed in the cortical bone chips from the diabetic
rats compared to controls (Fig. 6A,B). Quantification of the percentage of positively stained cells demonstrated
a significant increase in the diabetic rat bone chips vs the controls (Fig. 6D). This was confirmed by whole-bone
immunofluorescence (Fig. 7). We noted that sclerostin expression was not uniform throughout the bone, but was
randomly clustered in the cortex. This expression pattern did not appear to consistently localize to any one region
(proximal vs. mid vs. distal cortex) across specimens.

Discussion

Type 1 and type 2 diabetes are both associated with poor bone quality and increased risk of fracture, resulting in a
lower quality of life for patients and an increased burden on the healthcare system3,22. Sclerostin, a known inhibitor of bone formation, has been shown to be upregulated in the serum of patients suffering from type 1 and type
2 diabetes16,23,24. In addition, sclerostin levels can be regulated by other complications of diabetes such as chronic
kidney disease25 and inflammation26. Therefore, we investigated the effects of varying glucose levels in osteocytes
in vitro to determine the direct effect of chronically elevated glucose levels on osteocytes, as well as confirming
our findings with evaluation of streptozotocin-induced diabetes on sclerostin expression in vivo and ex vivo.
Dramatic elevation of Sost mRNA over 100 fold and sclerostin secretion over 6000 fold was observed in
IDG-SW3 osteocyte-like cells cultured long-term under high glucose conditions, offering evidence that the
upregulated sclerostin production by osteocytes in diabetes is mediated by local glucose levels. High glucose has
also been shown to increase sclerostin in the MLO-Y4 cell line approximately 2 fold27. As the MLO-Y4 cells have
been proposed to be a model of early osteocytes28 and as the IDG-SW3 represent a model of late osteoblast to
early osteocyte to late osteocyte17, the 6000 fold increase in the late osteocyte stage suggests a greater sensitivity
to glucose than late osteoblasts or early osteocytes. Given the dramatic increases in sclerostin observed, we next
examined the effects on matrix mineralization and bone formation markers in IDG-SW3 cells cultured under
high and low glucose conditions. No changes in expression of the osteoblast marker genes osterix (Osx) and
type I collagen (Col1a1) were observed in response to low or high glucose. Interestingly, increased expression
of the late osteoblast marker gene Kera was observed in the cells cultured under high glucose at the later time
points. Although the protein product of Kera, keratocan, is thought to play a role in matrix mineralization21, no
differences were observed in mineral deposition under differing glucose conditions as demonstrated by alizarin
red staining. Therefore, the function of the increased Kera expression under high glucose conditions is currently
unknown and will require further investigation.
Induction of high glucose levels in vivo also resulted in elevated Sost mRNA and robust sclerostin protein
expression by primary osteocytes. However, serum sclerostin levels were significantly decreased in the diabetic animals, suggesting a discord between local and serum sclerostin expression. This therefore suggests
that the increased sclerostin produced by the osteocytes is being retained within the bone. This suggests that
measuring serum sclerostin in diabetic patients may not be the most reliable method in evaluating biological
sclerostin activity and bone quality. It has recently been shown that in chronic kidney disease (CKD) patients
treated with glucocorticoids, serum sclerostin levels are not associated with bone sclerostin, as assessed by
immunohistochemistry29. Furthermore, similar to our observations in diabetic animals, bone SOST mRNA
and sclerostin protein levels are increased in patients following a kidney transplant, but serum sclerostin levels
are decreased30.
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Interestingly, primary osteocytes isolated from diabetic rats continued to express elevated sclerostin levels
even when cultured under normal glucose conditions. This suggests that diabetes induces long lasting changes
to the osteocyte and that high glucose levels are not required for the maintenance of these effects, at least ex vivo.
Furthermore, osteocytes isolated from control rats did not respond to short-term high glucose treatment by
increasing sclerostin and as well, osteocytes isolated from diabetic rats did not decrease sclerostin under short
term normal glucose treatment. This indicates that sustained exposure of osteocytes to high glucose is required to
induce the elevated sclerostin levels in the diabetic animals. The effects of high glucose levels on Sost and sclerostin protein expression are similar ex vivo in primary osteocytes and in long term, chronically exposed IDG-SW3
cells (Fig. 8A,B).
One of the most well described functions of sclerostin is as an anti-anabolic factor, inhibiting both bone
formation and mineralization by antagonizing the Wnt signaling pathway31,32. Increased Sost expression was
observed in the tibiae of diabetic mice compared with control mice33. However, in contrast with our findings in
the tibiae of diabetic rats, no differences were observed in the number of sclerostin positive osteocytes in the ulna
of the diabetic or control mice. This could be explained by the different anatomical sites used for the immunohistochemical analysis. The same study has also shown that treatment of diabetic mice with parathyroid-related
protein (PTHrP) downregulated sclerostin levels in these animals33 and the response to mechanical loading, as
evidenced by decrease in sclerostin-positive osteocytes, was blunted in the diabetic animals. PTHrP treatment
improved acquisition of bone mass and strength in these mice, suggesting that using PTHrP to regulate sclerostin
could be an important therapeutic strategy for maintaining bone health in diabetes.
In addition to negative effects on bone formation, diabetes has also been associated with reduced bone
resorption, resulting in low bone turnover34,35. Maintenance of bone quality relies upon the removal of old or
damaged bone and its replacement. Failure to remove this old or damaged bone, leads to defective bone remodeling and poor bone quality36,37. In addition, studies of streptozotocin-induced diabetes in rodents show marked
effects on bone, including decreased mineral apposition rate, decreased osteoblastogenesis, and reduction in
osteocalcin levels that are similar to spontaneously diabetic mice38–41. A decrease in serum carboxylated and
non-carboxylated osteocalcin was observed in the diabetic mice compared to controls (Supplemental Data).
Osteocalcin, while generally thought to be primarily produced by osteoblasts, is known to be expressed by osteocytes42. In addition, Atkins et al. showed that sclerostin treatment of late osteoblast/early osteocyte cells in vitro
significantly down-regulated osteocalcin expression, but had no effect on primary osteoblasts20. We consistently
saw no effects of elevated glucose on mineral formation in vitro, or on expression of osteoblastic genes in vitro or
in vivo.
Altogether, our findings suggest that diabetes induces longstanding changes in osteocytes, leading to upregulation of sclerostin. These effects appear to be mediated by local glucose concentrations and may play an important role in negatively regulating bone quality.
Received: 21 June 2019; Accepted: 10 October 2019;
Published: xx xx xxxx
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